Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Rexahn Pharmaceuticals, Inc. (RNN) Shares Plunged

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares are deep in the red today after the company announced plans to implement a 1-for-10 reverse stock split effective May 5, 2017. The company is likely doing so to stay listed on the NYSE MKT. Shareholders will receive cash in lieu of any fraction of a share that they would otherwise be entitled to receive.

CEO Peter D. Suzdak said, ‘I want to thank our shareholders for their continued support of Rexahn. Our board has determined that this is an appropriate time to implement a reverse split and we believe that it will enhance the appeal of our common stock to the financial community, including institutional investors and the general investing public. The continued commitment of our shareholders has allowed us to progress the clinical development of our targeted therapies for the treatment of cancer patients’.

Although the reverse stock split doesn’t affect Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s fundamentals, the split may make it easier for the stock to short, hence the decline today.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

None of the 742 top funds we track reported holding Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) at the end of Q4.

The Bottom Line

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares are lower due to a proposed reverse stock split. For more reading, check out ‘10 Most Popular Stocks Among Hedge Funds‘.

Disclosure:None

dna-163466_1280